Glass AI vs PathAI
Detailed side-by-side comparison to help you choose the right tool
Glass AI
🟡Low CodeAI Development Assistants
Clinical decision support AI that assists healthcare professionals with differential diagnosis, medical knowledge search, and evidence-based clinical reasoning.
Was this helpful?
Starting Price
FreemiumPathAI
🟢No CodeAutomation & Workflows
AI-powered digital pathology platform providing FDA-cleared digital pathology image management, biomarker analysis, and enterprise workflow management for laboratories and biopharma companies.
Was this helpful?
Starting Price
Custom quoteFeature Comparison
Scroll horizontally to compare details.
💡 Our Take
Choose Glass AI if your work is point-of-care reasoning, documentation, and differential diagnosis across general medicine. Choose PathAI if you are a pathologist or pathology lab needing AI-powered analysis of histopathology slides — PathAI is a specialty imaging tool and does not overlap with Glass's clinician workflow.
Glass AI - Pros & Cons
Pros
- ✓Bundles ambient scribing and clinical decision support in one subscription, replacing what would otherwise require two separate tools (typically $150-$400/month combined)
- ✓Pro tier at $90/month is competitive against standalone AI scribe products and includes unlimited usage of both scribing and decision support
- ✓Available on iOS, Android, and web, letting clinicians capture encounters on a phone in the exam room and review notes from a desktop later
- ✓Evidence-based diagnostic suggestions are grounded in current medical literature, helping clinicians consider comprehensive differentials for atypical or complex presentations
- ✓Educational value for medical residents and students — the structured problem-representation-to-differential workflow mirrors how clinical reasoning is formally taught
- ✓Max tier ($200/month) adds direct EHR integration so AI-generated notes flow into the chart without copy-paste
Cons
- ✗Restricted to licensed healthcare professionals — patients and non-clinical users cannot access the platform for self-diagnosis or general health questions
- ✗Specialty depth varies: well-suited to general internal medicine, family medicine, and emergency medicine, but may underperform on rare diseases or narrow subspecialties (e.g., advanced oncology subtypes, rare genetic disorders)
- ✗EHR integration is gated behind the $200/month Max tier — Pro users must still copy notes manually into their charting system
- ✗Output quality is bounded by the quality of clinician input: incomplete histories or vague problem representations produce weaker differentials
- ✗HIPAA and institutional compliance review is typically required before clinics can deploy ambient scribing on real patient encounters, adding rollout friction
PathAI - Pros & Cons
Pros
- ✓AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
- ✓Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
- ✓Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
- ✓Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
- ✓Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
- ✓Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.
Cons
- ✗Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
- ✗Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
- ✗Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
- ✗AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
- ✗The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.
Not sure which to pick?
🎯 Take our quiz →🔒 Security & Compliance Comparison
Scroll horizontally to compare details.
Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.